NASDAQ · MIRM
Healthcare · Biotechnology
$93.90
Up+$2.42 (+2.58%)
Updated Sep 16, 2026, 2:57 PM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MIRM closed at $93.90 after 20 trading sessions, down 6.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $97.57 | $97.57 | $93.57 | $93.90 | 948.71K |
| Sep 14, 2026 | $98.37 | $100.00 | $96.54 | $96.75 | 488.54K |
| Sep 11, 2026 | $102.78 | $103.275 | $97.80 | $98.22 | 441.1K |
| Sep 10, 2026 | $98.30 | $101.1799 | $97.48 | $100.61 | 587.04K |
| Sep 9, 2026 | $98.02 | $101.50 | $97.01 | $98.30 | 521.76K |
| Sep 8, 2026 | $98.49 | $101.8275 | $97.645 | $99.53 | 638.47K |
| Sep 4, 2026 | $99.08 | $101.99 | $99.08 | $100.90 | 350.96K |
| Sep 3, 2026 | $101.56 | $101.7299 | $99.055 | $100.63 | 453.04K |
| Sep 2, 2026 | $98.95 | $101.00 | $97.66 | $99.83 | 495.63K |
| Sep 1, 2026 | $97.84 | $99.69 | $97.47 | $98.34 | 398.38K |
| Aug 31, 2026 | $97.46 | $98.40 | $95.605 | $98.05 | 419.81K |
| Aug 28, 2026 | $99.43 | $100.06 | $96.545 | $97.46 | 426.51K |
| Aug 27, 2026 | $97.94 | $100.095 | $96.01 | $99.75 | 402.12K |
| Aug 26, 2026 | $97.95 | $98.80 | $95.00 | $98.51 | 571.06K |
| Aug 25, 2026 | $98.50 | $100.20 | $95.00 | $98.08 | 472.29K |
| Aug 24, 2026 | $96.31 | $97.85 | $95.49 | $96.72 | 367.57K |
| Aug 21, 2026 | $97.65 | $97.89 | $95.24 | $96.31 | 731.68K |
| Aug 20, 2026 | $100.73 | $101.96 | $96.98 | $97.07 | 352.68K |
| Aug 19, 2026 | $102.50 | $104.66 | $101.54 | $102.24 | 556.27K |
| Aug 18, 2026 | $99.50 | $101.26 | $99.00 | $100.87 | 518.11K |
The latest Smart Investors Daily articles mentioning MIRM.
MIRM research
Company profile and research snapshot.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | TD Cowen | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 10:00 AM EDTCompany ParticipantsChristopher Peetz -...
Yahoo · Sep 8, 2026
FOSTER CITY, Calif., September 08, 2026--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Yahoo · Sep 4, 2026
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 2, 2026
FOSTER CITY, Calif., September 02, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIRM.
